Bintrafusp alfa enhances the antitumor efficacy of anti-VEGF and VEGF receptor kinase inhibitors in preclinical solid tumor models.

被引：0

作者：

Yeung, Tsz-Lun ^{[1
]}

Lazorchak, Adam ^{[1
]}

Yu, Huakui ^{[1
]}

Qi, Jin ^{[1
]}

Qin, Guozhong ^{[1
]}

Marelli, Bo ^{[1
]}

Fu, Kai ^{[1
]}

Lan, Yan ^{[1
]}

机构：

[1] Serono Res & Dev Inst Inc, Billerica, MA USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

443

引用

页数：1

共 50 条

[11] NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
Xu, Chunxiao
Marelli, Bo
Qi, Jin
Qin, Guozhong
Yu, Huakui
Wang, Hong
Jenkins, Molly H.
Lo, Kin-Ming
Lan, Yan
TRANSLATIONAL ONCOLOGY, 2022, 16
[12] The hypertensive and haemodynamic actions of vandetanib and pazopanib, two anti-VEGF receptor tyrosine kinase inhibitors, in vivo
Carter, Joanne
Woolard, Jeanette
ANGIOGENESIS, 2014, 17 (04) : 961 - 961
[13] Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
Bagri, Anil
Berry, Leanne
Gunter, Bert
Singh, Mallika
Kasman, Ian
Damico, Lisa A.
Hong Xiang
Schmidt, Maike
Fuh, Germaine
Hollister, Beth
Rosen, Oliver
Plowman, Greg D.
CLINICAL CANCER RESEARCH, 2010, 16 (15) : 3887 - 3900
[14] Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
Pastuskovas, Cinthia V.
Mundo, Eduardo E.
Williams, Simon P.
Nayak, Tapan K.
Ho, Jason
Ulufatu, Sheila
Clark, Suzanna
Ross, Sarajane
Cheng, Eric
Parsons-Reponte, Kathryn
Cain, Gary
Van Hoy, Marjie
Majidy, Nicholas
Bheddah, Sheila
Chuh, Josefa dela Cruz
Kozak, Katherine R.
Lewin-Koh, Nicholas
Nauka, Peter
Bumbaca, Daniela
Sliwkowski, Mark
Tibbitts, Jay
Theil, Frank-Peter
Fielder, Paul J.
Khawli, Leslie A.
Boswell, C. Andrew
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 752 - 762
[15] Anti-tumor efficacy of the 3.19.3 ANG-2 antibody in combination with VEGF inhibitors in tumor xenograft models
Brown, Jeff
Cao, Zhu
Reimer, Corinne
Zhou, Qing
Kendrew, Jane
Ryan, Anderson
Jurgensmeier, Juliane
Emery, Steve
Blakey, David
CANCER RESEARCH, 2009, 69
[16] Pkm2 activation modulates the tumor-immune microenvironment and enhances response to checkpoint inhibitors in preclinical solid tumor models.
Sommakia, Salah
Pathi, Satya
Matsumura, Yuta
Allred, Curtis
Tyagi, Ethika
Lalonde, Matthew
Foulks, Jason
Siddiqui, Adam
Whatcott, Clifford
Bearss, David
Warner, Steven
CANCER RESEARCH, 2021, 81 (13)
[17] Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
de Almeida, Patricia E.
Mak, Judy
Hernandez, Genevive
Jesudason, Rajiv
Herault, Aurelie
Javinal, Vincent
Borneo, Jovencio
Kim, Jeong M.
Walsh, Kevin B.
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (06) : 806 - 818
[18] Antitumor efficacy of M3814 as a radiation sensitizer in neuroendocrine tumor (NET) preclinical models.
Chauhan, Aman
Rychahou, Piotr
Izumi, Tadahide
Arnold, Susanne M.
Anthony, Lowell Brian
Evers, Mark
Kunos, Charles
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[19] In vitro activity, anti-tumor efficacy and pharmacokinetics of indolin-2-one VEGF receptor inhibitors
Shawver, LK
Antonian, L
Sun, L
Tang, C
Wagner, GS
McMahon, G
Fong, TAT
Sukbuntherng, J
ANNALS OF ONCOLOGY, 1998, 9 : 76 - 76
[20] Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
McIntyre, Alan
Patiar, Shalini
Wigfield, Simon
Li, Ji-liang
Ledaki, Ioanna
Turley, Helen
Leek, Russell
Snell, Cameron
Gatter, Kevin
Sly, William S.
Vaughan-Jones, Richard D.
Swietach, Pawel
Harris, Adrian L.
CLINICAL CANCER RESEARCH, 2012, 18 (11) : 3100 - 3111

← 1 2 3 4 5 →